SiBone (NASDAQ:SIBN) Insider Anthony Recupero Sells 21,049 Shares

SiBone (NASDAQ:SIBN) insider Anthony Recupero sold 21,049 shares of the stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $15.40, for a total transaction of $324,154.60. Following the sale, the insider directly owned 243,418 shares of the company’s stock, valued at approximately $3,748,637.20. This represents a 7.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

SiBone Price Performance

Shares of NASDAQ SIBN traded up $0.49 during trading on Wednesday, hitting $15.74. The company had a trading volume of 569,275 shares, compared to its average volume of 430,376. SiBone has a 52 week low of $12.49 and a 52 week high of $21.89. The business’s 50-day moving average is $17.97 and its 200 day moving average is $16.86. The company has a market cap of $682.96 million, a P/E ratio of -30.86 and a beta of 0.69. The company has a debt-to-equity ratio of 0.21, a quick ratio of 6.62 and a current ratio of 7.97.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. ANTIPODES PARTNERS Ltd acquired a new position in SiBone in the 4th quarter valued at approximately $29,000. Royal Bank of Canada boosted its stake in shares of SiBone by 98.5% during the 4th quarter. Royal Bank of Canada now owns 1,483 shares of the company’s stock valued at $29,000 after buying an additional 736 shares during the period. Caitong International Asset Management Co. Ltd grew its holdings in shares of SiBone by 64,700.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,944 shares of the company’s stock valued at $38,000 after acquiring an additional 1,941 shares in the last quarter. State of Alaska Department of Revenue acquired a new position in shares of SiBone in the third quarter worth $39,000. Finally, Kemnay Advisory Services Inc. acquired a new position in shares of SiBone in the fourth quarter worth $53,000. 98.11% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the company. Needham & Company LLC lifted their price target on SiBone from $24.00 to $27.00 and gave the stock a “buy” rating in a research note on Tuesday, December 16th. Morgan Stanley boosted their price target on shares of SiBone from $20.00 to $23.00 and gave the company an “overweight” rating in a report on Tuesday, December 2nd. TD Cowen raised shares of SiBone to a “strong-buy” rating in a research note on Tuesday, January 27th. Truist Financial lifted their price objective on shares of SiBone from $21.00 to $23.00 and gave the stock a “buy” rating in a research report on Thursday, December 18th. Finally, Canaccord Genuity Group increased their target price on SiBone from $26.00 to $27.00 and gave the company a “buy” rating in a report on Wednesday, December 17th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $24.33.

About SiBone

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.